US pharma market growth forecast to slow until 2008
Growth of the US pharmaceutical market is forecast to return a compound annual growth rate of 9.7% over the period 2003-2008, according to Wood Mackenzie's new sales forecasting and analytical tool, Productview.
Growth of the US pharmaceutical market is forecast to return a compound annual growth rate of 9.7% over the period 2003-2008, according to Wood Mackenzie's new sales forecasting and analytical tool, Productview.
'Medicare reform, a number of key patent expiries and relatively slim r&d pipelines are likely to combine to impact the sales growth of the world's leading companies in the US market,' said Simon Smyth, senior analyst at Wood Mackenzie Life Sciences.
'However, the continued strong performance of key biotechnology companies such as Amgen and Genentech and fast-growing pharmaceutical companies such as Eli Lilly and Hoffmann-La Roche should ensure that US growth continues to outpace that of the global market.'
Productview provides an informed, independent product-by-product sales analysis of both worldwide and US-only ethical drug sales trends. This detailed analysis of more than 850 marketed and r&d products is designed to profile the sales outlook for companies, therapeutic areas and product classes. Productview also provides comparative rankings of the world's leading pharmaceutical and biotechnology companies and their ethical drug products. A separately priced module of Productview provides product-by-product US-only sales forecasts for the top 15 pharmaceutical companies.